• Search for:
21Oct
NexFabric Debuts Human-Verified Industrial AI for Laser Cutting at EuroBLECH 2026

Hannover, Germany, October 21st, 2026, FinanceWire

Italian-built NexCut helps sheet metal shops tell a settings problem from a machine fault, and gives newer operators a guided way to learn what veterans know.

NexFabric today presented NexCut in Europe for the first time, at EuroBLECH 2026 on the stand of Esautomotion (Euronext Growth Milan: ESAU), Hall 15, Stand E28, after a first showing at CIIF in Shanghai. NexCut is the first laser-cutting application of the NexFabric industrial AI platform. Built in Italy, it pairs AI-assisted analysis with checks the operator confirms, so manufacturing teams can diagnose production problems without handing the decision to the machine.

Factories are losing the people who know their machines best. In Germany, 12.9 million workers, close to 30% of the workforce, will reach retirement age by 2036, according to the Federal Statistical Office. In Italy, companies reported difficulty filling 47.8% of planned hires, with CNC operators and welders among the hardest roles to fill, according to a CGIA analysis of Unioncamere Excelsior data. NexCut is built for that handover. A junior operator learns the diagnostic routine on the job, guided step by step, instead of spending years picking it up beside a veteran. Every diagnosis is saved as a procedure the next shift can reuse.

NexCut addresses a practical challenge in laser cutting: telling a problem with process settings from an issue with the machine or its hardware. Take a common case. Dross starts building on the underside of the parts. A less experienced operator may slow the cut or raise gas pressure. If the real cause is a dirty lens or a worn nozzle, that change wastes material and the fault stays. NexCut has the operator check the hardware first and confirm what they find. If there’s a hardware problem, it won’t clear the machine to run until it’s fixed.

Here’s how it works. Each laser cutter gets its own NexCut kit: a touchscreen operator station at the machine and a connected hardware module that brings in process signals from the cutter. When cut quality drops, NexCut combines those signals with physical checks the operator carries out and confirms, covering the lens, gas, focus position, cutting height, nozzle and machine stability. It narrows down the likely cause, explains why, and points to the fix. The operator makes the call. Every step is logged, so the process stays traceable and repeatable, and a central dashboard gives production managers a view across all connected machines.

“Running a laser cutter well takes years of experience, and even experienced operators still make mistakes,” said Stefano D’Andria, CEO & Founder of NexFabric. “NexCut is there to help and teach. Any operator can use it, whatever their experience, and the decision always stays with the person at the machine.”

The first proof of concept is running under real operating conditions at Soluzioni Markaurelio S.r.l. in Avezzano, Italy. It is testing NexCut against clear targets: an average guided diagnosis of 7 to 11 minutes, a 50 to 70% reduction in setup time, startup scrap and machine stoppages, and new operators working on their own within two to four weeks.

NexCut is built for manufacturers across Europe that run laser cutters. Operators get step-by-step guidance at the machine. Owners keep the know-how in-house when experienced staff leave. NexFabric plans to work with multiple industrial partners and dealers, broadening access while preserving manufacturer choice.

“Industrial AI must increase human decision-making capability, not replace it,” D’Andria added. “We’re starting in Italy, where our R&D is, and building for factories across Europe.”

D’Andria is at EuroBLECH through October 23 and available for interviews at the stand. To book a time, contact Orian Tal at orian@thepitch.media.

Manufacturers, dealers and technology partners can learn more at https://nexcut.ai or contact info@nexfabric.ai.

About NexFabric

NexFabric is an industrial AI platform built in Italy. It connects manufacturing processes and human expertise through guided diagnosis and human verification. Its first application, NexCut, focuses on laser cutting. Learn more at https://nexfabric.ai.

Contact

Orian Tal
The Pitch
orian@thepitch.media
21Oct
NexFabric Debuts Human-Verified Industrial AI for Laser Cutting at EuroBLECH 2026

Hannover, Germany, October 21st, 2026, FinanceWire

Italian-built NexCut helps sheet metal shops tell a settings problem from a machine fault, and gives newer operators a guided way to learn what veterans know.

NexFabric today presented NexCut in Europe for the first time, at EuroBLECH 2026 on the stand of Esautomotion (Euronext Growth Milan: ESAU), Hall 15, Stand E28, after a first showing at CIIF in Shanghai. NexCut is the first laser-cutting application of the NexFabric industrial AI platform. Built in Italy, it pairs AI-assisted analysis with checks the operator confirms, so manufacturing teams can diagnose production problems without handing the decision to the machine.

Factories are losing the people who know their machines best. In Germany, 12.9 million workers, close to 30% of the workforce, will reach retirement age by 2036, according to the Federal Statistical Office. In Italy, companies reported difficulty filling 47.8% of planned hires, with CNC operators and welders among the hardest roles to fill, according to a CGIA analysis of Unioncamere Excelsior data. NexCut is built for that handover. A junior operator learns the diagnostic routine on the job, guided step by step, instead of spending years picking it up beside a veteran. Every diagnosis is saved as a procedure the next shift can reuse.

NexCut addresses a practical challenge in laser cutting: telling a problem with process settings from an issue with the machine or its hardware. Take a common case. Dross starts building on the underside of the parts. A less experienced operator may slow the cut or raise gas pressure. If the real cause is a dirty lens or a worn nozzle, that change wastes material and the fault stays. NexCut has the operator check the hardware first and confirm what they find. If there’s a hardware problem, it won’t clear the machine to run until it’s fixed.

Here’s how it works. Each laser cutter gets its own NexCut kit: a touchscreen operator station at the machine and a connected hardware module that brings in process signals from the cutter. When cut quality drops, NexCut combines those signals with physical checks the operator carries out and confirms, covering the lens, gas, focus position, cutting height, nozzle and machine stability. It narrows down the likely cause, explains why, and points to the fix. The operator makes the call. Every step is logged, so the process stays traceable and repeatable, and a central dashboard gives production managers a view across all connected machines.

“Running a laser cutter well takes years of experience, and even experienced operators still make mistakes,” said Stefano D’Andria, CEO & Founder of NexFabric. “NexCut is there to help and teach. Any operator can use it, whatever their experience, and the decision always stays with the person at the machine.”

The first proof of concept is running under real operating conditions at Soluzioni Markaurelio S.r.l. in Avezzano, Italy. It is testing NexCut against clear targets: an average guided diagnosis of 7 to 11 minutes, a 50 to 70% reduction in setup time, startup scrap and machine stoppages, and new operators working on their own within two to four weeks.

NexCut is built for manufacturers across Europe that run laser cutters. Operators get step-by-step guidance at the machine. Owners keep the know-how in-house when experienced staff leave. NexFabric plans to work with multiple industrial partners and dealers, broadening access while preserving manufacturer choice.

“Industrial AI must increase human decision-making capability, not replace it,” D’Andria added. “We’re starting in Italy, where our R&D is, and building for factories across Europe.”

D’Andria is at EuroBLECH through October 23 and available for interviews at the stand. To book a time, contact Orian Tal at orian@thepitch.media.

Manufacturers, dealers and technology partners can learn more at https://nexcut.ai or contact info@nexfabric.ai.

About NexFabric

NexFabric is an industrial AI platform built in Italy. It connects manufacturing processes and human expertise through guided diagnosis and human verification. Its first application, NexCut, focuses on laser cutting. Learn more at https://nexfabric.ai.

Contact

Orian Tal
The Pitch
orian@thepitch.media
21Oct
Sundas Naqvi: Moving Cities Does Not Mean Leaving Your Sound Behind

Chicago, Illinois, 21st October 2026, ZEX PR WIRE, Chicago jazz and folk vocalist Sundas Naqvi shares the lesson she learned when she moved her music from southern England to the American Midwest, and what she now tells other musicians who relocate.

Leaving One Sound for Another

Sundas Naqvi grew up in southern England, singing in school choirs and small community concerts before she found jazz and folk music at university. That sound, built around British choir traditions and acoustic folk, was the only musical language she knew.

In her late twenties, she moved to Chicago. The city had its own musical history, built on blues, jazz clubs, and a folk scene that worked differently than anything she had performed in before. She had to figure out where her voice fit inside it.

“I thought I was bringing a finished sound with me,” Naqvi says. “What I actually brought was a starting point.”

What Changed, and What Did Not

Naqvi did not rebuild her style from scratch. The jazz standards she loved stayed. The folk influences she picked up in England stayed too. What changed was how she used them.

Chicago’s jazz lounges rewarded a different kind of phrasing than the rooms she had performed in back home. Its coffeehouses wanted something quieter and more conversational. Private events and seasonal festivals each asked for their own pacing. She learned to read a room the way she once read sheet music.

“The songs didn’t change,” she says. “I changed how I told them.”

That shift shaped the storytelling that now runs through her sets, songs built around resilience, family, and the small moments that connect strangers in a room. Naqvi says those themes came less from any single influence and more from paying attention to what audiences in her new city responded to.

The Lesson She Tells Other Musicians

Naqvi now volunteers with youth music education programs around Chicago, leading beginner songwriting workshops and vocal sessions. She says the musicians she meets, young and experienced alike, often make the same mistake she almost made: treating a new city, a new audience, or even a new venue as a place to perform an existing sound rather than a place to grow one.

“You don’t have to choose between where you came from and where you are,” she says. “But you do have to let the new place change you a little. If it doesn’t, you’re not really there yet.”

Her advice to musicians who relocate, or who are simply trying a new room for the first time, is to treat the first several performances as listening exercises. Watch how people react to pacing, silence, and song choice before deciding what to keep and what to adjust.

“A song that works in one room can fall flat in another,” Naqvi says. “That’s not a failure. That’s information.”

Still Bringing England Into the Room

Naqvi returns to England when she can, to see family and lifelong friends. She says those visits keep her connected to where her musical instincts started, even as her sound has grown around Chicago’s own traditions.

She still reads British literature alongside contemporary fiction, a habit she picked up long before she ever sang jazz. She spends free time exploring Chicago’s older neighborhoods and photographing its architecture, work she says sharpens the same instinct for detail she uses when she is writing a song.

“Noticing a building’s small details isn’t that different from noticing what makes a lyric land,” she says. “Both come down to paying attention to things most people walk past.”

That habit of attention, more than any single technique, is what she now tries to pass on in her workshops: slow down, notice the room, and let the place you are in actually shape the art you make there.

About Sundas Naqvi

Sundas Naqvi is an independent jazz and folk vocalist, songwriter, and occasional vocal coach based in Chicago, Illinois. She performs at neighborhood jazz lounges, coffeehouses, private events, and seasonal festivals throughout the city, blending jazz standards with contemporary folk influences. She also volunteers with youth music education programs, leading beginner songwriting workshops and vocal sessions for children in Chicago’s local arts community.
21Oct
Rabbi Steve Karro’s Message: Give Something Back Before the Holidays Arrive

Miami, Florida, 21st October 2026, ZEX PR WIRE, Rabbi Steve Karro is asking his community to make one concrete act of giving part of their holiday preparation this year.

A season that asks something of us

Every year, the weeks before the holidays fill up fast. Cleaning, cooking, travel, gifts. Rabbi Steve Karro has spent decades studying the parts of Jewish tradition that ask us to slow that rush down and make room for someone else.

As a rabbi and scribe based in Miami Beach, Florida, he sees the holiday season as more than a checklist of preparations. He sees it as a yearly reminder to look outward.

“Every situation, I ask what the Creator expects from me,” Rabbi Karro said. “Before the holidays, the answer is usually simple. Give something. Give it now, not later.”

The invitation

Rabbi Karro is encouraging people in his community to take on a simple practice ahead of this holiday season: one act of direct giving to someone nearby, done before the holiday itself begins, not during it and not after.

“It does not need to be large,” he said. “It needs to happen before the holiday starts, not get folded into it. That timing matters. It says the giving came from you, not from the season telling you to.”

Why the order matters

Rabbi Karro draws a distinction between giving that happens because a holiday requires it, and giving that happens because a person chooses it ahead of time.

“When you give during the holiday, you are following the calendar,” he said. “When you give before it, you are following your own decision. Both are good. But the second one changes something in you.”

He points to family life as the frame he uses to think about this.

“When your closest family is happy, and the people around them are happy too, that is the real measure,” he said. “Giving before the holiday is one way to widen that circle a little further out from your own table.”

What giving back can look like

Rabbi Karro is not prescriptive about the form giving should take. He suggests people start with someone they already know needs something, rather than searching for a cause far from home.

“Start close,” he said. “A neighbor. Someone at your synagogue. Someone in your family nobody has checked on in a while. The person right in front of you is usually the answer.”

He also encourages people to think about what they can give beyond money: time, a skill, a meal, a conversation.

“Everyone has something they know how to give,” he said. “Teaching, cooking, fixing something, listening. Find yours and give it before the holiday, not during it.”

A practice, not a one-time gesture

Rabbi Karro hopes this becomes something people return to each year, not a single gesture tied to this season alone.

“I want to see this duplicated,” he said. “Not from one person, but from many people who hear about it and decide to do their own version. That is how something small becomes something that lasts.”

He also connects the practice to teaching, which he considers central to his work as a rabbi and scribe.

“Teaching what I have learned means more people can do good for the people around them,” he said. “That is the whole point.”

About Rabbi Steve Karro

Rabbi Steve Karro is a rabbi, scribe, artist, and teacher based in Miami Beach, Florida. Born in Russia, he moved to Jerusalem at age 10 and began his Hebrew education there. At 13, he continued his studies at Yeshiva Ponovich in Bnei Brak, and by 19 he had earned his rabbinic certificate and diploma. Rabbi Karro works internationally as a Judaica calligraphy and oil painting artist, and as a scribe specializing in restoring old Torah scrolls, writing new Torah scrolls, mezuzahs, and tefilin, and checking Torah scrolls, mezuzahs, and tefilin for communities around the world.
21Oct
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

Boca Raton, Florida, October 21st, 2026, FinanceWire

  • Final pre-MAA package submitted to MHRA on October 20, 2026
  • Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks
  • US BLA expected to be submitted in Q2, 2027

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has revised prior guidance to indicate that faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.

Following MHRA feedback on the final pre-MAA package, INmune Bio plans to finalize and submit a complete application in February, 2027, replacing the sequential rolling submission previously planned to begin in late 2026. Based on progress in chemistry, manufacturing and controls (CMC) and discussions with regulatory advisors, the Company believes this approach could accelerate potential UK approval by approximately six weeks from prior guidance.

The Company anticipates an MHRA response within three to six months after submission, subject to application validation, agency review and any requests for additional information. Submission of the complete package is intended to support assessment of the clinical, manufacturing and quality data together.

“This is a remarkable achievement by the whole CMC team and our external regulatory advisors allowing us to accelerate the potential approval for Ebstrocel for children with RDEB,” said Mark Lowdell, Chief Scientific Officer of INmune Bio. “Our progress allows us to bring forward the anticipated timeline to commercial supply, subject to approval, for children and families waiting for treatment.”

In parallel, INmune Bio has engaged U.S. regulatory advisors with rare disease expertise to prepare and submit a Type B meeting request to the U.S. Food and Drug Administration (FDA). Subject to feedback from that meeting, the Company plans to submit a Biologics License Application (BLA) in the second quarter of 2027, seeking traditional or accelerated approval, as appropriate.

“Based on positive feedback from our regulatory consultants in the U.S, we are prioritizing our FDA application ahead of an EMA submission, building on Ebstrocel’s U.S. Orphan Drug and Rare Pediatric Disease designations,” said David Moss, Chief Executive Officer of INmune Bio. “With potential UK and U.S. approvals in 2027, we are approaching a pivotal year. Approval in either or both markets would mark a major milestone for INmune Bio and bring Ebstrocel closer to patients and families living with RDEB.”

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

  • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
  • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:

David Moss

Chief Executive Officer

(561) 710-0512

info@inmunebio.com

Contact

Head of Investor Relations
Daniel Carlson
dcarlson@inmunebio.com
(415) 509-4590
21Oct
Hola Prime Simplifies Prop Trading Rules With Launch Of It’s Rulebook

New York, USA, October 21st, 2026, FinanceWire

The rulebook consolidates account requirements, removes three funded account restrictions and maintains transparent change logs so traders can track rule updates.

Hola Prime, a global proprietary trading firm, today announced the launch of The Rulebook, a consolidated rulebook designed to make trading rules and account conditions easier to access, understand and track.

The updated rulebook brings key information covering challenge passing criteria, conditions, trading rules, breach conditions and account requirements into one place. It also maintains transparent change logs, allowing traders to follow updates to the rules and understand how the firm’s requirements evolve over time.

By centralising this information, Hola Prime aims to give traders a clearer reference point throughout their trading journey, from understanding account conditions before trading to reviewing the rules that apply to their accounts.

All Rules in One Place, With Transparent Change Logs

Prop trading rules and account conditions play an important role in how traders manage their accounts. Having access to the applicable requirements in one place helps traders understand their obligations without having to navigate multiple resources.

The Rulebook brings these requirements together in a single document, giving traders one central reference for the rules governing their accounts. The rulebook is designed to make access to information more straightforward and give traders greater clarity on the requirements they are expected to follow.

Three Restrictions Removed

As part of the update, Hola Prime has removed three restrictions that previously applied to funded accounts:

  • The 60% maximum concentration per trade
  • The 70% maximum margin rule
  • The three-minute Stop Loss deadline

These changes form part of Hola Prime’s broader effort to simplify its trading conditions while making the applicable rules easier for traders to review.

A Clearer Process for Breach Appeals

While The Rulebook provides a central reference for trading rules and account conditions, Hola Prime also offers traders a way to challenge a breach they believe has been applied incorrectly.

Traders who have grounds to dispute a breach can submit an appeal through the available appeal process. Hola Prime’s Risk Team reviews the circumstances and provides a written explanation of the outcome, whether the original breach is upheld or reversed.

This process gives traders a formal channel to raise concerns and seek clarification when they believe an account decision does not align with the applicable rules.

Making Rule Transparency Part of the Trader Experience

Somesh Kapuria, CEO of Hola Prime, said: “Clear rules are an important part of a fair trading environment. Traders should be able to find the conditions that apply to their accounts without having to search across multiple resources. With The Rulebook, we are bringing those requirements together and maintaining transparent change logs so traders can keep track of updates. We have also removed three restrictions from Sim. funded accounts as part of our ongoing effort to make our trading conditions clearer and more straightforward.”

The Rulebook is available to Hola Prime traders on the official Hola Prime website.

About Hola Prime

Hola Prime is a global proprietary trading firm offering funded trading accounts to traders worldwide. The firm provides access to trading opportunities across major financial instruments, including forex, commodities and indices, with programs designed for different trading approaches.

Known for its 1-Hour Payout model, Hola Prime has received industry recognition, including the Global Most Transparent Prop Firm 2025 award by Finance Magnates and the Fastest Payout Prop Firm MEA 2026 award by UF Awards.

For more information, users can visit www.holaprime.com.

Contact

Manya Bhardwaj
HolaPrime
contactus@holaprime.com
21Oct
INmune Bio Advances Ebstrocel™ Toward Potential UK Approval in Mid-2027

Boca Raton, Florida, October 21st, 2026, FinanceWire

  • Final pre-MAA package submitted to MHRA on October 20, 2026
  • Full MAA submission targeted for early February 2027, under a revised strategy that could bring potential UK approval forward by approximately six weeks
  • US BLA expected to be submitted in Q2, 2027

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has submitted its final pre-Marketing Authorisation Application (pre-MAA) package to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Ebstrocel™ (CORDStrom™), its investigational cell therapy for recessive dystrophic epidermolysis bullosa (RDEB). The company has revised prior guidance to indicate that faster-than-expected manufacturing progress supports a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review.

Following MHRA feedback on the final pre-MAA package, INmune Bio plans to finalize and submit a complete application in February, 2027, replacing the sequential rolling submission previously planned to begin in late 2026. Based on progress in chemistry, manufacturing and controls (CMC) and discussions with regulatory advisors, the Company believes this approach could accelerate potential UK approval by approximately six weeks from prior guidance.

The Company anticipates an MHRA response within three to six months after submission, subject to application validation, agency review and any requests for additional information. Submission of the complete package is intended to support assessment of the clinical, manufacturing and quality data together.

“This is a remarkable achievement by the whole CMC team and our external regulatory advisors allowing us to accelerate the potential approval for Ebstrocel for children with RDEB,” said Mark Lowdell, Chief Scientific Officer of INmune Bio. “Our progress allows us to bring forward the anticipated timeline to commercial supply, subject to approval, for children and families waiting for treatment.”

In parallel, INmune Bio has engaged U.S. regulatory advisors with rare disease expertise to prepare and submit a Type B meeting request to the U.S. Food and Drug Administration (FDA). Subject to feedback from that meeting, the Company plans to submit a Biologics License Application (BLA) in the second quarter of 2027, seeking traditional or accelerated approval, as appropriate.

“Based on positive feedback from our regulatory consultants in the U.S, we are prioritizing our FDA application ahead of an EMA submission, building on Ebstrocel’s U.S. Orphan Drug and Rare Pediatric Disease designations,” said David Moss, Chief Executive Officer of INmune Bio. “With potential UK and U.S. approvals in 2027, we are approaching a pivotal year. Approval in either or both markets would mark a major milestone for INmune Bio and bring Ebstrocel closer to patients and families living with RDEB.”

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. The Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

  • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning to regulatory filing phases, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. Biologics License Application (BLA) submission.
  • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform designed to selectively neutralize soluble TNF (sTNF) and reduce neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates remain in clinical development stage and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, including Ebstrocel™, XPro™ and INKmune™ trial results, timing of key milestones, future plans or expectations, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™, XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts:

David Moss

Chief Executive Officer

(561) 710-0512

info@inmunebio.com

Contact

Head of Investor Relations
Daniel Carlson
dcarlson@inmunebio.com
(415) 509-4590
21Oct
Hola Prime Simplifies Prop Trading Rules With Launch Of It’s Rulebook

New York, USA, October 21st, 2026, FinanceWire

The rulebook consolidates account requirements, removes three funded account restrictions and maintains transparent change logs so traders can track rule updates.

Hola Prime, a global proprietary trading firm, today announced the launch of The Rulebook, a consolidated rulebook designed to make trading rules and account conditions easier to access, understand and track.

The updated rulebook brings key information covering challenge passing criteria, conditions, trading rules, breach conditions and account requirements into one place. It also maintains transparent change logs, allowing traders to follow updates to the rules and understand how the firm’s requirements evolve over time.

By centralising this information, Hola Prime aims to give traders a clearer reference point throughout their trading journey, from understanding account conditions before trading to reviewing the rules that apply to their accounts.

All Rules in One Place, With Transparent Change Logs

Prop trading rules and account conditions play an important role in how traders manage their accounts. Having access to the applicable requirements in one place helps traders understand their obligations without having to navigate multiple resources.

The Rulebook brings these requirements together in a single document, giving traders one central reference for the rules governing their accounts. The rulebook is designed to make access to information more straightforward and give traders greater clarity on the requirements they are expected to follow.

Three Restrictions Removed

As part of the update, Hola Prime has removed three restrictions that previously applied to funded accounts:

  • The 60% maximum concentration per trade
  • The 70% maximum margin rule
  • The three-minute Stop Loss deadline

These changes form part of Hola Prime’s broader effort to simplify its trading conditions while making the applicable rules easier for traders to review.

A Clearer Process for Breach Appeals

While The Rulebook provides a central reference for trading rules and account conditions, Hola Prime also offers traders a way to challenge a breach they believe has been applied incorrectly.

Traders who have grounds to dispute a breach can submit an appeal through the available appeal process. Hola Prime’s Risk Team reviews the circumstances and provides a written explanation of the outcome, whether the original breach is upheld or reversed.

This process gives traders a formal channel to raise concerns and seek clarification when they believe an account decision does not align with the applicable rules.

Making Rule Transparency Part of the Trader Experience

Somesh Kapuria, CEO of Hola Prime, said: “Clear rules are an important part of a fair trading environment. Traders should be able to find the conditions that apply to their accounts without having to search across multiple resources. With The Rulebook, we are bringing those requirements together and maintaining transparent change logs so traders can keep track of updates. We have also removed three restrictions from Sim. funded accounts as part of our ongoing effort to make our trading conditions clearer and more straightforward.”

The Rulebook is available to Hola Prime traders on the official Hola Prime website.

About Hola Prime

Hola Prime is a global proprietary trading firm offering funded trading accounts to traders worldwide. The firm provides access to trading opportunities across major financial instruments, including forex, commodities and indices, with programs designed for different trading approaches.

Known for its 1-Hour Payout model, Hola Prime has received industry recognition, including the Global Most Transparent Prop Firm 2025 award by Finance Magnates and the Fastest Payout Prop Firm MEA 2026 award by UF Awards.

For more information, users can visit www.holaprime.com.

Contact

Manya Bhardwaj
HolaPrime
contactus@holaprime.com
21Oct
Saudi Content Creator Nawaf Alzahrani Launches Official Blog

Saudi Arabia, 21st Oct 2026, Grand Newswire – Saudi digital content creator Nawaf Alzahrani has officially launched his personal blog, marking a new step in his digital media presence and providing a dedicated platform for sharing updates, exclusive releases, and project announcements.

Saudi Content Creator Nawaf Alzahrani Launches Official Blog

The new blog aims to strengthen Alzahrani’s online presence by offering readers a central destination for following his work, exploring project developments, and accessing new digital content.

A New Platform for Exclusive Content

Alzahrani’s official blog is designed to serve as an editorial platform for project coverage, specialized insights, and direct updates. The initiative creates an additional channel through which audiences can stay informed about his activities and upcoming releases.

By launching a dedicated blog, Alzahrani is expanding his digital publishing presence and establishing a platform to support his long-term development goals.

A Vision for Future Growth

Commenting on the launch, Alzahrani emphasized his ambitions for the future and the role of the new platform in supporting his broader vision.

“Launching this platform provides a structured environment to support our future growth and deliver higher-value content to our community,” Alzahrani stated.

The blog reflects his commitment to developing new ways to share content, communicate updates, and build stronger connections with his audience.

Upcoming Releases and Updates

The official blog is now live and open to the public. A series of digital releases and special updates is scheduled for publication in the coming period.

Readers can visit the platform to follow future announcements and discover updates about Alzahrani’s projects as new content becomes available.

About Nawaf Alzahrani

Nawaf Alzahrani is a Saudi digital content creator. Channel owner H2rfez fM and a blog News Shop His newly launched personal blog provides a dedicated online platform for project updates, digital releases, specialized insights, and announcements about his work.

Media Contact

Organization: H2rfez fM

Contact
Person: Nawaf Alzahrani

Website:

https://smarline.ne

Email:

H2rfez1@gmail.com

Country:Saudi Arabia

The post Saudi Content Creator Nawaf Alzahrani Launches Official Blog
appeared first on Grand Newswire.
It is provided by a third-party content provider. Grand Newswire makes no
warranties or representations in connection with it.

21Oct
INmune Bio Establishes Global Commercialization Framework for Ebstrocel™ Through Strategic Agreement with Uniphar

Boca Raton, Florida, October 21st, 2026, FinanceWire

INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announced that it has entered into a Master Services Agreement with Uniphar Durbin Ireland Limited (“Uniphar”) establishing a scalable framework to support international access, distribution and commercialization of Ebstrocel™, the Company’s allogeneic stromal cell therapy for Recessive Dystrophic Epidermolysis Bullosa (RDEB). INmune Bio initially intends to use the framework to pursue named-patient access in selected European countries and in the Middle East and North Africa (MENA), subject to applicable law and country-specific statements of work. The relationship may subsequently expand across Europe and other territories by mutual agreement.

The Company expects named-patient access to be an important component of its international commercialization strategy for Ebstrocel™. Where permitted by local law and implemented through statements of work, this pathway may allow physicians to request Ebstrocel™ for individual eligible patients before local marketing approval or broad commercial availability.

The Uniphar framework is designed to provide the Company with scalable international commercial infrastructure, beginning with named-patient supply, and potentially expanding to broader commercial distribution as regulatory approvals, pricing and reimbursement are secured in individual countries. Depending on the services agreed in individual statements of work, Uniphar may support regulatory feasibility assessments, market access, product storage and distribution, healthcare-provider and treatment-site onboarding, order-to-cash services, medical information, pharmacovigilance support and end-to-end shipment tracking. By leveraging Uniphar’s established infrastructure rather than building country-by-country capabilities internally, the Company believes this model provides a capital-efficient path to establish Ebstrocel™’s international commercial footprint and scale as additional markets become available.

“This agreement marks an important step in moving Ebstrocel™ from clinical development toward commercialization and bringing Ebstrocel to patients internationally,” said David Moss, Chief Executive Officer of INmune Bio. “Uniphar provides access to established market-access, distribution and order-to-cash capabilities across multiple international markets without requiring INmune Bio to build those capabilities country by country. We believe this provides a capital-efficient way to pursue named-patient opportunities in appropriate markets while building the physician relationships, treatment-center experience and commercial infrastructure needed to support broader international commercialization.”

 “We are pleased to partner with INmune Bio as it prepares Ebstrocel for international commercialization,” said Ruth Rostron, Head of Expanded Access at Uniphar. “Uniphar has built an integrated global platform to help innovative medicines navigate the complexities of international access, distribution and commercialization. We believe our infrastructure and experience are well suited to support INmune Bio’s strategy for Ebstrocel, beginning with named-patient access opportunities and expanding as the product progresses through its regulatory and commercial journey.”

About Ebstrocel™

Ebstrocel™ (pobistrocel) is INmune Bio’s investigational, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy being developed through the Company’s CORDStrom™ platform for the treatment of RDEB. The platform is designed to address donor variability and manufacturing inconsistency. Ebstrocel™ is investigational and has not been approved by the FDA, MHRA, EMA or any other regulatory authority.

About Uniphar Plc.

Uniphar is a trusted global partner to pharma, medtech and biotech, delivering solutions that connect medicines and technologies with patients worldwide. With over 57 years of experience and partnerships with 200+ multinational clients, Uniphar combines deep expertise, global infrastructure and market insight to meet the evolving needs of the life sciences sector.

Uniphar Pharma integrates Development, Clinical, Access, Medical, Commercial, Distribution and Global Sourcing to support the full product lifecycle – from early-stage research through to commercialization and beyond. Uniphar’s unified platform spans regulatory strategy, clinical trial support, medical affairs, market access, patient engagement, commercial services, distribution and supply chain.

Operating across 160 countries with a global team of 3,600+, Uniphar bridges manufacturers, healthcare providers, and patients — accelerating access to innovative therapies, improving patient outcomes, and delivering value across the healthcare ecosystem.

From molecule to market and beyond.

For more information, please visit www.uniphar.com 

About INmune Bio Inc.

INmune Bio Inc. is a publicly traded (NASDAQ: INMB), late-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. Moving beyond early-stage exploration, the Company’s clinical-development strategy centers on advanced precision medicine, matching drug mechanisms directly to patient biology to optimize clinical outcomes.

INmune Bio is actively advancing two late-stage product platforms toward registrational milestones:

  • CORDStrom™: A proprietary, pooled, allogeneic, human umbilical cord-derived mesenchymal stromal cell platform engineered to address the historical clinical challenges of donor variability and manufacturing inconsistency. Following successful clinical readouts in RDEB, the platform is transitioning toward regulatory and commercial readiness, with an MAA planned for the UK MHRA in 2026 and EU EMA in 2027, alongside a planned U.S. regulatory pathway and development of international access and distribution infrastructure.
  • XPro1595™: A Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform that selectively neutralizes soluble TNF (sTNF) to reduce pathological neuroinflammation without compromising protective immune function. Backed by recently granted FDA Fast Track designation and successful regulatory alignment from an End-of-Phase 2 meeting, XPro1595™ is positioned for an integrated Phase 2b/3 seamless adaptive registrational program in neuroinflammation-enriched early Alzheimer’s disease.

To learn more about INmune Bio’s pipeline and its approach to harnessing the innate immune system, please visit www.inmunebio.com.

Forward Looking Statements

The Company’s product candidates are investigational, and there can be no assurance that any clinical, regulatory or commercial objective will be achieved. Any statements contained in this press release related to the development or commercialization of product candidates and other business and financial matters, including without limitation, trial results and data, timing of key milestones, future plans or expectations, the scope and implementation of the Uniphar relationship, the execution of statements of work, the availability and timing of named-patient or expanded-access sales, potential revenue, potential expansion across Europe or into Latin America, the anticipated capital efficiency of the distribution model, and the prospects for receiving regulatory approval or commercializing or selling any product or drug candidates, may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to several risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements because of these risks and uncertainties. CORDStrom™ (EbstrocelTM, pobistrocel), XPro1595™ (XPro™, pegipanermin), and INKmune™ have either finished clinical trials, are still in clinical trials or are preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA), the UK MHRA or any regulatory body and there cannot be any assurance that they will be approved by the FDA, the UK MHRA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements to reflect any event or circumstance that may arise after the date of this release.

INmune Bio Contacts: 

David Moss 

Chief Executive Officer 

(561) 710-0512 

info@inmunebio.com

Daniel Carlson 

Head of Investor Relations 

(415) 509-4590 

dcarlson@inmunebio.com

Uniphar Contacts:

Media Contacts:

Uniphar: Heather.Hopkin@teamtala.com and Beth.Oshea@teamtala.com

Contact

Uniphar
NPS_Ebstrocel@uniphar.com